Hôpital Lapeyronie

International audience

Acute kidney injury (AKI) is a frequent and severe complication among critically ill patients. Circulating dipeptidyl peptidase 3 (cDPP3), an enzyme released upon cellular injury, has been implicated in hemodynamic instability and organ dysfunction. Its role in severe AKI remains poorly defined. We aimed to assess the prognostic significance of cDPP3 in critically ill patients with severe AKI. In this post hoc analysis of the AKIKI 2 study, we included ICU patients with severe AKI (KDIGO stage 3) who were receiving (or had received) invasive mechanical ventilation and/or vasopressor support and had available blood samples at inclusion. Patients were stratified according to cDPP3 concentration using a predefined cutoff of 40 ng/mL. The primary outcome was 28-day mortality; secondary outcomes were organ support-free days. Among 287 included patients, 143 (49.8%) had cDPP3 concentrations above 40 ng/mL. High cDPP3 was associated with increased 28-day mortality (hazard ratio 1.95; 95% confidence interval 1.37-2.87, p < 0.001). Furthermore, high cDPP3 was associated with fewer days alive without vasopressors (mean difference - 5.59; 95% CI - 8.29 to - 2.78, p < 0.001), invasive mechanical ventilation (mean difference - 6.23; 95% CI - 8.89 to - 3.36, p < 0.001), or renal replacement therapy (mean difference - 6.35; 95% CI - 9.14 to - 3.26, p < 0.001). After adjustment for baseline markers of severity, both the associations with 28-day mortality and organ support-free days remained significant. In critically ill patients with severe AKI, a high cDPP3 concentration at diagnosis is associated with increased short-term mortality and prolonged dependence on organ support.

To establish French recommendations for the management of people living with hand osteoarthritis (OA) on behalf of the French Society of Rheumatology (SFR) and of the French Society of Physical and Rehabilitation Medicine (SOFMER). A systematic review of the literature, including systematic reviews, meta-analyses, and randomized controlled trials on pharmacological and non-pharmacological treatments, was conducted from inception until November 24, 2023. Based on this review and expert consensus, a multidisciplinary group of 25 healthcare professionals-including rheumatologists, physical and rehabilitation medicine physicians, hand surgeons, general practitioner, geriatrician, occupational therapists, physiotherapists, and patients-formulated the recommendations. Each statement was assigned a level of evidence, a grade of recommendation, and a level of agreement based on EULAR standardized procedures for recommendations. The group established four general principles and 11 specific recommendations. The general principles emphasize treatment objectives, individualized management, patient education, and a multimodal approach combining non-pharmacological and pharmacological therapies. Four specific recommendations address non-pharmacological strategies, including exercise, ergonomic advice, assistive devices, orthoses and heat applications. The group advises against the use of electromagnetic waves, laser therapy, acupuncture, or kinesiotaping. Seven specific recommendations cover pharmacological treatments, advocating for topical and oral NSAIDs, acetaminophen, chondroitin sulfate for symptom relief, low-dose oral corticosteroids for inflammatory flares, and intra-articular steroid injections for inflammatory painful interphalangeal OA. Given the current data, the group advises against the use of conventional synthetic or biological disease-modifying anti-rheumatic drugs (DMARDs). These recommendations provide a structured approach for the management of people living with hand OA in France, aligning with national healthcare practices and patient needs.

Major Depressive Disorder (MDD) is a debilitating psychiatric disorder that is a leading cause of disability worldwide. Although treatment with antidepressants, such as Selective Serotonin Reuptake Inhibitors (SSRIs), has demonstrated clinical efficacy, the "trial and error" approach in choosing the most effective antidepressant treatment for each patient allows for only a subset of patients to achieve response to the first line of treatment. Circular RNAs (circRNAs), are highly stable and brain-enriched non-coding RNAs that are mainly derived from the backsplicing and covalent joining of exons and introns of protein-coding genes. They are known to be important for brain development and function, cross the blood-brain-barrier, and be highly sensitive to changes in both synaptic activity and neuronal receptor signaling. Here we present evidence that expression of the brain-enriched circRNA, CDR1as, is associated with symptomatic response to SSRI treatment, and regulated by serotonin and Brain-Derived Neurotrophic Factor (BDNF) receptor activity. We present data using circRNA-specific PCR in baseline whole blood samples from two independent cohorts, drawn from the Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC) and the Biomarkers of ANTidepressant RESponse (ANTARES) clinical studies, showing that before treatment CDR1as is differentially expressed between future symptomatic responders and non-responders to treatment with the SSRI sertraline. Additional data from naturalistic antidepressant response studies further highlight the association between CDR1as and antidepressant effects of SSRIs as a class. In addition, we show that CDR1as levels are altered following sertraline treatment in responders with the trajectory of change post-treatment associated with long-term remission. Furthermore, we report that levels of CDR1as in the blood can specifically predict remission with SSRI treatment, but not response/remission with Placebo or Bupropion treatments. Lastly, we provide evidence in animal mechanistic and neuronal culture studies, suggesting mouse Cdr1as is strongly regulated by 5-HT2A and BDNF receptor signaling. Taken together, our data identify a brain-enriched circRNA associated with known mechanisms of antidepressant response that can serve as a blood biomarker for predicting response and remission with SSRI treatment.

IntroductionThe Latarjet procedure is the mainstay treatment in high-demand patients with substantial glenoid bone loss or after failed capsulolabral repairs. Patients typically return to sport (RTS) within 6 months postoperatively, requiring intensive rehabilitation. Current rehabilitation protocols focus on mobility, strength and stability. Yet, psychological factors, such as fear of reinjury, are the main reason not to RTS. Therefore, this study aims to determine whether integrating psychological interventions into postoperative rehabilitation improves patient-reported shoulder function compared with physical therapy alone.Methods and analysisThis monocentric randomised controlled trial will enrol 52 patients undergoing a Latarjet procedure for anterior shoulder instability. Participants will be equally and randomly assigned to either postoperative physical therapy combined with cognitive behavioural therapy or physical therapy alone. Eligibility criteria include patients aged 18–67 years undergoing an open or arthroscopic Latarjet procedure at our institution. Exclusion criteria include posterior or multidirectional instability, rotator cuff tear, prior shoulder surgery, anxiety disorder, using anxiolytics, neurological disorder, systemic disease, previous hospitalisation for shoulder pain and proximal humerus fractures.The primary outcome is the Western Ontario Shoulder Index at 6 months postoperatively. Secondary outcomes include incidence of recurrent dislocations, RTS and return-to-work rates, Tampa Scale of Kinesiophobia for Shoulder Instability, subjective shoulder value and visual analogue score for pain at 6 months postoperatively as well as the Shoulder Instability Return to Sport after Injury scale at 4.5 months postoperatively.Ethics and disseminationThis study was approved by the French Committee of Person Protection West I. The national registration number is 2023-A02057-38. The study has been registered at Clinicaltrials.gov with trial registration number NCT06154889. Patients are not financially compensated for participation and are allowed to withdraw from the study at any time without any preconditions. The final results of the study will be submitted for publication in a peer-reviewed journal and an abstract of the study will be submitted to international scientific meetings by the end of 2026. Data will be made available by the corresponding author on reasonable request.Registration detailsThe study has been registered at Clinicaltrials.gov with trial registration number NCT06154889. The trial sponsor is Vivalto Santé.Trial registration numberNCT06154889.

Background/Objectives: Poiseuille’s law describes the influence of radius, length, viscosity, and pressure on the flow of Newtonian fluids. Although bone cement is a non-Newtonian, shear-thinning, and polymerizing material that does not comply with this law in any predictive or quantitative sense, its qualitative principles may offer a didactic framework for understanding factors that affect injectability during cementoplasty. The objective of this Technical Note is to provide an educational and conceptual interpretation of Poiseuille’s law as it relates to trocar selection, cement behavior, and procedural planning. Methods: This work presents theoretical calculations based on the r4/L component of Poiseuille’s equation, using manufacturer-specified internal radii for commonly used trocars. Relative flow rates were computed as r4/L ratios normalized to a 13-gauge, 15 cm trocar. Conceptual viscosity profiles illustrate qualitative differences among cements over time. A representative, fully anonymized clinical example is provided to illustrate the integration of these conceptual principles into practice. No experimental measurements were performed. Results: Theoretical calculations show that trocar radius has the strongest influence on theoretical flow, with an exponential effect (r4), whereas increasing trocar length proportionally reduces flow. Conceptual viscosity curves demonstrate the rapid rise in viscosity during polymerization and highlight the importance of timing and cement selection. The clinical example illustrates how trocar choice, access planning, and cement viscosity are adapted to lesion morphology and cortical integrity. Conclusions: Poiseuille’s law cannot model or predict bone cement behavior and has no procedural or clinical validity in cementoplasty. Its use in this Technical Note is strictly educational, providing a qualitative framework to illustrate general relationships between equipment characteristics, viscosity evolution, and resistance during injection, without offering clinical guidance or implying any impact on procedural planning, safety, or outcomes.